Stockreport

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 [Yahoo! Finance]

Actuate Therapeutics, Inc. - Common stock  (ACTU) 
PDF clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen [Read more]